Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The only thing that was holding me back was me
Tirzepatide Research# SURPASS program (Type 2 diabetes): Five Phase 3 trials demonstrating superior HbA1c reduction compared to insulin glargine, semaglutide, and insulin degludec SURMOUNT program (Obesity): Phase 3 trials showing up to 20.9% weight loss at 72 weeks FDA approvals : Mounjaro (May 2022) for T2D
GLP-1 medications are FDA-approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27-29.9) with at least one weight-related comorbidity
Ozempic and the Risk of nAMD A recent article in JAMA Ophthamology (June 2025) suggests that vascular changes triggered by GLP-1 activity may trigger or worsen nAMD in some patients, especially those who are older, diabetic, or already at risk for macular degeneration
US$ 21.22
US$ 27.14
US$ 29.60
US$ 26.63
US$ 27.86
US$ 26.58
US$ 23.56
US$ 26.58
